Oculis Holding AG Updates Clinical Programs at R&D Day
Ticker: OCSAW · Form: 6-K · Filed: Apr 15, 2025 · CIK: 1953530
| Field | Detail |
|---|---|
| Company | Oculis Holding Ag (OCSAW) |
| Form Type | 6-K |
| Filed Date | Apr 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trials, drug-development, r&d-update
Related Tickers: OCLS
TL;DR
Oculis AG (OCLS) dropped clinical trial updates today, focusing on OCS-01, OCS-02, and OCS-05.
AI Summary
On April 15, 2025, Oculis Holding AG held an R&D Day to provide updates on its clinical programs. Key highlights included progress on Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema, the design of a Phase 2/3 study for Licaminlimab (OCS-02) in dry eye disease, and expanded data analysis from the Phase 2 ACUITY trial of Privosegtor (OCS-05) for acute optic neuritis.
Why It Matters
These updates provide insight into the progress of Oculis' drug candidates, which could impact future treatment options for serious eye conditions.
Risk Assessment
Risk Level: medium — Clinical trial updates inherently carry risk due to the uncertainty of trial outcomes and regulatory approvals.
Key Players & Entities
- Oculis Holding AG (company) — Registrant
- April 15, 2025 (date) — Date of R&D Day and press release
- OCS-01 (drug_candidate) — Eye drops for diabetic macular edema
- Licaminlimab (OCS-02) (drug_candidate) — For dry eye disease
- Privosegtor (OCS-05) (drug_candidate) — For acute optic neuritis
FAQ
What is the status of the Phase 3 DIAMOND trials for OCS-01?
The filing indicates that Oculis Holding AG provided updates on its Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema during its R&D Day on April 15, 2025.
What is the purpose of the Phase 2/3 study for Licaminlimab (OCS-02)?
The study design for Licaminlimab (OCS-02) for dry eye disease was presented, with the filing mentioning a Phase 2/3 study design.
What new data was presented regarding Privosegtor (OCS-05)?
Oculis Holding AG presented expanded data analysis from its Phase 2 ACUITY trial of Privosegtor (OCS-05) in acute optic neuritis.
When did Oculis Holding AG hold its R&D Day?
Oculis Holding AG held its R&D Day on April 15, 2025.
What type of report is this filing?
This filing is a Form 6-K, which is a Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 15, 2025 regarding Oculis Holding AG (OCSAW).